Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04951219 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
A Phase 3 study of Non-alcoholic Fatty Liver Disease, sponsored by Madrigal Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT04951219: Active Phase 3 study of Non-alcoholic Fatty Liver Disease, sponsored by Madrigal Pharmaceuticals.
NCT04951219 is a Phase 3 study of Non-alcoholic Fatty Liver Disease that is active but no longer recruiting, run by Madrigal Pharmaceuticals. The registered enrollment target is 1,000 participants, above the 160-participant average among 57 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (525% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04951219, a Phase 3 study of Non-alcoholic Fatty Liver Disease, is active but no longer recruiting, sponsored by Madrigal Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Conditions Studied
Interventions
- DRUG Resmetirom
Study Locations (20)
California
- Fresno Clinical Research Center - Fresno
- National Research Institute - Huntington Park - Huntington Park
- Ruane Clinical Research Group - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- National Research Institute - Los Angeles - Los Angeles
- National Research Institute - Panorama City - Panorama City
- San Fernando Valley Health Institute - West Hills
Arizona
- Arizona Liver Health - Chandler - Chandler
- East Valley Family Physicians - Chandler
- The Institute For Liver Health - Glendale - Glendale
- The Institute For Liver Health - Tucson - Tucson
- Adobe Gastroenterology - Tucson
Florida
- Excel Medical Clinical Trials - Boca Raton
- Covenant Research - Fort Myers
- Velocity Clinical Research, Hallandale Beach (MD Clinical) - Hallandale
- Floridian Clinical Research - Hialeah
- Nature Coast Clinical Research - Inverness - Inverness
Alabama
- Central Research Associates - Birmingham
Arkansas
- Arkansas Gastroenterology - North Little Rock
Colorado
- South Denver Gastroenterology - Swedish Medical Center Office - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2021-07-09 |
| Est. Completion | 2026-04 |
| Phase | Phase 3 |
What the registry record for NCT04951219 still lists
NCT04951219 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 160-participant average among 57 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (525% higher).
The record links to 1 condition, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 1 intervention - of which Resmetirom is the first listed.
NCT04951219 names 20 study sites across 6 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT04951219 about?
NCT04951219 is a clinical study titled "A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)". A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
What is the current status of trial NCT04951219?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2021-07-09. Estimated completion is 2026-04.
What conditions does trial NCT04951219 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT04951219?
The interventions under investigation include: Resmetirom (DRUG).
Who is sponsoring clinical trial NCT04951219?
This trial is sponsored by Madrigal Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04951219 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04951219's enrollment target sits among peer trials
1,000 4th of 57 higher than 54 of 57 other Non-alcoholic Fatty Liver Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-alcoholic Fatty Liver Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
RECRUITING · Phase 3
-
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
RECRUITING · Phase 3
-
Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes
COMPLETED · Phase 3
-
Intermittent Fasting for NAFLD in Adults
RECRUITING · NA
-
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
RECRUITING · NA
-
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI